Drugs / U69
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07350863 | Jun → Dec 2026 expected | refractory precursor T-lymphoblastic lymphoma/leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U69 | “The investigational product is the CXCR4-enhanced CCR9 Chimeric Antigen Receptor T-Cell Injection (CXCR4/CCR9 CAR-T, U69).” NCT07350863 ↗ |
| Known as | CXCR4/CCR9 CAR-T | “The investigational product is the CXCR4-enhanced CCR9 Chimeric Antigen Receptor T-Cell Injection (CXCR4/CCR9 CAR-T, U69).” NCT07350863 ↗ |
| Modality | Cell therapy | “CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection” NCT07350863 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT07350863 ↗ |